Predictive factors for response to treatment in patients with advanced renal cell carcinoma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Investigational new drugs

• Publication date

  2012-05-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10637-012-9836-4PMID 22644070
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• Gastrosplenic fistula from Hodgkin's lymphoma.

  2009cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

  2009cited by this paper
• Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC).

  2009cited by this paper
• Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas

  2009cited by this paper
• Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma

  2008cited by this paper
• Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• Hypoxia-inducible factor (HIF) 1{alpha} and 2{alpha} levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC)

  2008cited by this paper
• Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

  2008cited by this paper
• Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy

  2008cited by this paper
• Renal cell carcinoma

  2007cited by this paper
• Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) -targeted therapy in metastatic renal cell carcinoma (RCC)

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Prospective evaluation of carbonic anhydrase IX (CAIX) as a molecular marker in metastatic renal cell carcinoma

  2007cited by this paper
• Renal-cell carcinoma--molecular pathways and therapies.

  2007cited by this paper
• PTEN expression in renal cell carcinoma and oncocytoma and prognosis

  2007cited by this paper
• Impact of immune parameters on long-term survival in metastatic renal cell carcinoma.

  2006cited by this paper
• Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer

  2006cited by this paper
• Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma.

  2005cited by this paper
• Renal cell carcinoma in relation to cigarette smoking: Meta‐analysis of 24 studies

  2005cited by this paper
• Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer

  2005cited by this paper
• Cancer Statistics, 2005

  2005cited by this paper
• Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms

  2004cited by this paper
• Tobacco and cancer: recent epidemiological evidence.

  2004cited by this paper
• An Antisense Oligodeoxynucleotide to p21Waf1/Cip1 Causes Apoptosis in Human Breast Cancer Cells1

  2003cited by this paper
• An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells.

  2003cited by this paper
• The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy.

  2003cited by this paper
• The hypoxia-inducible factor-1α is a negative factor for tumor therapy

  2003cited by this paper
• p21Waf1/Cip1 as a therapeutic target in breast and other cancers.

  2003cited by this paper
• Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.

  2003cited by this paper
• Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.

  2003cited by this paper
• Obesity and Renal Cell Cancer—a Quantitative Review

  2002cited by this paper
• Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

  2002cited by this paper
• Obesity and renal cell cancer – a quantitative review

  2001cited by this paper
• Overweight as an avoidable cause of cancer in Europe

  2001cited by this paper
• Epidemiologic aspects of renal cell cancer.

  2000cited by this paper
• Management of renal cell carcinoma.

  2000cited by this paper
• Cancer statistics, 2000

  2000cited by this paper
• Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

  1999cited by this paper
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

  1999cited by this paper
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

  1999cited by this paper
• Serum interleukin-6 levels in patients with thrombocytosis.

  1992cited by this paper
• A Case‐Control Study of Diet and Risk of Renal Adenocarcinoma

  1990cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• Renal-cell Carcinoma

  1976cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Index for rating diagnostic tests

  1950cited by this paper

• miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma

  2022cites this paper
• Carbonic anhydrase IX immunohistochemistry has potential to predict renal cell carcinoma outcomes: A systematic review and meta-analyses.

  2019cites this paper
• miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma

  2019cites this paper
• Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer

  2019cites this paper
• Intratumoral Predictive Markers in Metastatic Renal Cancer Patients

  2018cites this paper
• Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

  2017cites this paper
• Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.

  2017cites this paper
• New biomarkers and treatment strategies in renal cell cancer

  2016cites this paper
• Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges

  2015cites this paper
• Induction of Epithelial-Mesenchymal Transition via Activation of Epidermal Growth Factor Receptor Contributes to Sunitinib Resistance in Human Renal Cell Carcinoma Cell Lines

  2015cites this paper
• Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma.

  2015cites this paper
• PTEN: Multiple Functions in Human Malignant Tumors

  2015cites this paper
• Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use.

  2015cites this paper
• Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

  2015cites this paper
• Induction of epithelial–mesenchymal transition via activation of epidermal growth factor receptor constitutes to sunitinib resistance in human renal cell carcinoma cell lines

  2015cites this paper
• CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.

  2014cites this paper
• Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer

  2014cites this paper
• Prognostic Value of Carbonic Anhydrase IX Immunohistochemical Expression in Renal Cell Carcinoma: A Meta-Analysis of the Literature

  2014cites this paper
• Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

  2014cites this paper
• A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma.

  2014influential citation
• Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.

  2014cites this paper
• Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma

  2013cites this paper
• Vascularity of primary and metastatic renal cell carcinoma specimens

  2013cites this paper
• Biomarkers for tyrosine kinase inhibitors in renal cell cancer

  2012cites this paper